Cardio3 BioSciences, a Mont-Saint-Guibert, next to Louvain-La-Neuve, Belgium-based biotechnology company, raised €19m in equity funding.
Of the €19m raised, €7m is in new equity committed by existing investors with €12m resulting from the conversion of existing convertible loans.
Founded in 2007 and led by Christian Homsy , CEO, Cardio3 BioSciences focuses on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases by leveraging research collaborations in the US and in Europe with, among other, Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.
The company intends to use these funds for the on-going clinical development its lead product, C-Cure®, currently tested in Europe in a Phase III trial (CHART-1 – Congestive Heart failure Cardiopoietic Regenerative Therapy) and for the preclinical development of other product candidates.
FinSMEs
08/05/2013
Related News
11/01/2012: Cardio3BioSciences Secures €3.1M in Funding